MSB 2.17% $1.13 mesoblast limited

Ann: Appendix 4C Quarterly Activity Report, page-216

  1. 126 Posts.
    lightbulb Created with Sketch. 551
    I think this is a very important slide from the last trial results presentation, showing that control patients who received dexamethasone showed no survival benefit. But once treated with Remestemcel-L + dexamethasone, a significant survival benefit of 75% at day 60 and 77% at day 90 was observed (in patients<65).

    No treatment for ARDS has ever shown such a significant mortality reduction in any patient population. These are the sickest Covid-19 patients who are in ICU on mechanical ventilation who now have an 86% chance of survival compared to just 55% with current SOC.

    https://hotcopper.com.au/data/attachments/3420/3420454-ad6970a46a2e59cd39d562fcf9607344.jpg
    https://hotcopper.com.au/data/attachments/3420/3420457-2a64bd764ba595ea373641616d91d34c.jpg

 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.13
Change
-0.025(2.17%)
Mkt cap ! $1.284B
Open High Low Value Volume
$1.15 $1.16 $1.11 $7.363M 6.488M

Buyers (Bids)

No. Vol. Price($)
5 94863 $1.13
 

Sellers (Offers)

Price($) Vol. No.
$1.13 5000 2
View Market Depth
Last trade - 16.10pm 26/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.